Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Niagen Bioscience (NAGE) EBT: 2011-2024

Historic EBT for Niagen Bioscience (NAGE) over the last 12 years, with Dec 2024 value amounting to $8.9 million.

  • Niagen Bioscience's EBT rose 155.59% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.3 million, marking a year-over-year increase of 1331.11%. This contributed to the annual value of $8.9 million for FY2024, which is 279.32% up from last year.
  • Niagen Bioscience's EBT amounted to $8.9 million in FY2024, which was up 279.32% from -$4.9 million recorded in FY2023.
  • Niagen Bioscience's 5-year EBT high stood at $8.9 million for FY2024, and its period low was -$27.1 million during FY2021.
  • Moreover, its 3-year median value for EBT was -$4.9 million (2023), whereas its average is -$4.9 million.
  • In the last 5 years, Niagen Bioscience's EBT tumbled by 36.15% in 2021 and then skyrocketed by 279.32% in 2024.
  • Over the past 5 years, Niagen Bioscience's EBT (Yearly) stood at -$19.9 million in 2020, then slumped by 36.15% to -$27.1 million in 2021, then surged by 31.33% to -$18.6 million in 2022, then soared by 73.49% to -$4.9 million in 2023, then surged by 279.32% to $8.9 million in 2024.